Lévy A, Blanchard P, Janot F, Temam S, Bourhis J, Daly-Schveitzer N, Tao Y
Service d'oncologie-radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
Département de chirurgie ORL, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
Cancer Radiother. 2014 Jan;18(1):1-6. doi: 10.1016/j.canrad.2013.06.047. Epub 2013 Dec 3.
Squamous cell carcinoma of larynx with subglottic extension is a rare location described to carry a poor prognosis. The aim of this study was to analyze outcomes and feasibility of definitive radiotherapy in patients with squamous cell carcinoma.
Between 1998 and 2012, 56 patients with squamous cell carcinoma were treated at our institution and included in the analysis. Patients received definitive radiotherapy/chemoradiotherapy alone (63%) or after induction chemotherapy (37%) at our institute.
The 5-year actuarial overall survival, progression-free survival and specific survival were 64% (CI 95%: 48-90), 45% (CI 95%: 28-61), 88% (CI 95%: 78-98), respectively, with median follow-up of 74 months. The 5-year locoregional control was 69% (CI 95%: 56-83) and the 5-year distant control was 95% (CI 95%: 89-100). There was no difference in overall survival and locoregional control according to front-line treatments or between primary subglottic cancer and glotto-supraglottic cancers with subglottic extension. In the multivariate analysis, performance status of at least 1 and positive N stage were the only predictors for overall survival (hazard ratio [HR] [CI 95%]: 6.5 [1.3-34; P=0.03] and 11 [1.6-75; P=0.02], respectively). No difference of locoregional control was observed according to the first received therapy. The univariate analysis retrieved that T3-T4 patients had a lower locoregional control (HR: 3.1; CI 95%: 1.1-9.2, P=0.04), but no prognostic factor was retrieved in the multivariate analysis. In patients receiving a larynx preservation protocol, 5-year larynx preservation rate was 88% (CI 95%: 78-98), and 58% in T3 patients. The 5-year larynx preservation rate was 91% (CI 95%: 79-100) and 83% (CI 95%: 66-100) for patients who received radiotherapy/chemoradiotherapy or induction chemotherapy as a front-line treatment, respectively.
This analysis suggests that the results for squamous cell carcinoma patients treated with radiotherapy/chemoradiotherapy are comparable to those obtained for other laryngeal tumors. This thus suggests the feasibility of laryngeal preservation protocols for infringement subglottic for selected cases. Further studies are needed to clarify these preliminary data.
伴有声门下扩展的喉鳞状细胞癌是一种罕见部位,预后较差。本研究的目的是分析鳞状细胞癌患者接受根治性放疗的疗效和可行性。
1998年至2012年期间,我院治疗了56例鳞状细胞癌患者并纳入分析。患者在我院单独接受根治性放疗/同步放化疗(63%)或诱导化疗后接受放疗/同步放化疗(37%)。
5年精算总生存率、无进展生存率和特异性生存率分别为64%(95%置信区间:48 - 90)、45%(95%置信区间:28 - 61)、88%(95%置信区间:78 - 98),中位随访时间为74个月。5年局部区域控制率为69%(95%置信区间:56 - 83),5年远处转移控制率为95%(95%置信区间:89 - 100)。根据一线治疗方式,或原发性声门下癌与伴有声门下扩展的声门 - 声门上癌之间,总生存率和局部区域控制率无差异。多因素分析中,体能状态至少为1和N分期阳性是总生存率的唯一预测因素(风险比[HR][95%置信区间]:分别为6.5[1.3 - 34;P = 0.03]和11[1.6 - 75;P = 0.02])。根据首次接受的治疗方式,未观察到局部区域控制率的差异。单因素分析显示,T3 - T4期患者的局部区域控制率较低(HR:3.1;95%置信区间:1.1 - 9.2,P = 0.04),但多因素分析未发现预后因素。在接受喉保留方案的患者中,5年喉保留率为88%(95%置信区间:78 - 98),T3期患者为58%。接受放疗/同步放化疗或诱导化疗作为一线治疗的患者,5年喉保留率分别为91%(95%置信区间:79 - 100)和83%(95%置信区间:66 - 100)。
该分析表明,接受放疗/同步放化疗的鳞状细胞癌患者的结果与其他喉部肿瘤患者的结果相当。这表明对于部分病例,声门下侵犯采用喉保留方案是可行的。需要进一步研究以阐明这些初步数据。